Shares of Axsome Therapeutics (NASDAQ: AXSM) were soaring 12.7% higher as of 11:19 a.m. ET on Thursday. Perhaps the most likely explanation for Axsome jumping today is that large institutional investors could be buying the biotech stock. Another possibility is that some short-sellers are covering their positions, creating upward pressure on the share prices in the process.
Google parent Alphabet reported earnings below analysts' expectations on Thursday.
Shares of apparel company Hanesbrands (NYSE: HBI) dropped like a rock on Thursday after the company provided lackluster financial guidance and announced some substantial pivots to management's priorities. As of 11:40 a.m. ET, Hanesbrands stock was down 23% -- particularly painful, considering the market is soaring today. On one hand, fourth-quarter revenue of $1.47 billion beat guidance from Hanesbrands' management.
Investors got a reminder of the capabilities of Palantir Technologies' (NYSE: PLTR) products, helping to reinforce the bull case for the stock. Palantir came to market in late 2020 to great enthusiasm, based largely on the reputation of its technology. The data-analytics provider is credited with helping the Pentagon find Osama bin Laden and with flagging the Bernie Madoff Ponzi scheme.
When Cathie Wood speaks, people listen. The chief executive of Ark Investment Management has had a far-from-perfect record when it comes to her investment choices -- not to mention not exactly flattering feedback from CNBC's Jim Cramer. When asked what stock Wood would choose she won a million dollar lottery and was forced to choose a stock for ten years, Wood's pick was just as disruptive as her reputation.
Two major automakers want to put more fuel cell vehicles on the road -- and Plug Power investors took note.
Yahoo Finance Live’s Rachelle Akuffo breaks down the expectations for Apple, Amazon, and Alphabet earnings.
There's more evidence now favoring medical marijuana legalization. But medical marijuana is already legal in most states.
Shipments hit a nine-year low at 1.21 billion units in 2022, IDC added. The weakness in demand for lower-end phones has also begun to hit premium devices, which fetch companies like Qualcomm higher prices for their chips. A supply glut in the smartphone market, which was the one of the first to show softening in demand following soaring pandemic-led growth, is an added blow.
Shares of Carnival (NYSE: CCL) jumped 34.2% in January compared to where it closed out 2022, according to data provided by S&P Global Market Intelligence, as the cruise line operator, which is working to return to full capacity, said it would raise its prices. The increase in certain rates suggests there is still strong, latent demand for ocean-going travel that bodes well for the cruise company's profitability. Revenue per passenger cruise days for the period was up sequentially from the third quarter and ahead of 2019 even though occupancy was a full 19 percentage points lower than three years ago.
Higher oil price is likely to have aided BP's Q4 earnings.
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.
Dividend stocks are a great way to mitigate downside risk, hedge against inflation, and generate reliable levels of passive income. Closed-end funds, real estate investment trusts (REITs), and some actively managed diversified holding companies are purpose-built to return an outsize portion of cash flows to shareholders via regular distributions. Arbor Realty Trust (NYSE: ABR) is a REIT with a current annualized yield of 10.75%.
At this time, I'll now turn the conference over to Hooper Stevens, senior vice president of investor relations and finance. Today, we will have prepared remarks from Jennifer Witz, our chief executive officer; and Sean Sullivan, our chief financial officer.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Top health insurance company Humana (NYSE: HUM) wasn't necessarily tops with investors on Wednesday. After reporting its latest set of quarterly figures, the company's share price bumped slightly higher, by 0.3%, which wasn't high enough to beat the S&P 500 index's more than 1% increase. It's not that Humana's results for the fourth quarter 2022 were bad or uninspiring; it's just that they didn't excel.
For the third day in a row, Tesla (NASDAQ: TSLA) stock is riding higher -- up 4.3% as of 10:10 a.m. ET. The Federal Reserve's decision to raise interest rates only 25 basis points yesterday is probably part of the reason for that -- indeed, growth stocks in general seem happy to run today, with the entire Nasdaq up nearly 2%. Tesla's plan to cut the prices of its electric cars, you see -- not just in the U.S., but in China as well -- is having its intended effect of stoking consumer demand.
Change doesn't have to be bad.
Leading iBuyer Opendoor (NASDAQ: OPEN) was having an excellent day on Thursday. As of 3 p.m. EST, the real estate disruptor's stock had risen by 14% for the day and has now more than tripled from its 52-week low in just over a month. There isn't any company-specific news driving the news higher, but there has been a surge in optimism for the real estate market in general.
Have a question about working with your financial adviser or looking to hire a new one? Email picks@marketwatch.com.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo Finance 
Yahoo Finance Plus